AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171

Trial StartAHB-171Positive

AI Analysis

Summary

AusperBio announced the first patient dosing in a clinical study of its investigational hepatitis B candidate AHB-171. The company is a biopharmaceutical firm focused on targeted oligonucleotide therapeutics for chronic hepatitis B treatment.

Clinical Trial Data

Outcome Details

First patient dosed in clinical study

Importance:5/10

Sentiment:

0.50

hepatitis Boligonucleotide therapeuticsclinical trialfirst patient dosed

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on August 3, 2026 9:30 AM

Read Original